Senior Vice President, Pipeline Research
Karen is an immunologist by training and has 30 years’ experience in drug discovery in a range of therapeutic areas including oncology, inflammatory disease and neurology. She has broad experience in small molecule and antibody drug discovery and in cell and gene therapy. At AdaptImmune, Karen is the SVP of Pipeline Research, leading the teams developing novel engineered T cell therapies for the treatment of cancer. Karen joined AdaptImmune from GSK where she was Vice President, Head of the Immunology Innovation Fund with responsibility for sourcing and evaluating internal and external project opportunities in immunology, across multiple therapeutic areas including oncology. Prior to this, she led GSK’s Cytokine, Chemokine and Complement Discovery Performance Unit taking projects from target identification and validation through to late-stage clinical trials. Prior to joining GSK, she held roles as Head of Biology for UCB Pharma, Vertex and British Biotech. Karen started her research career at Imperial College in London, carrying out research on signal transduction mechanisms using cell, biochemical and imaging techniques.